Images of medication Zepbound Generic Name tirzepatide Strength 10 mg/0.5 mL injection (single-dose vial) Availability Prescription only Drug Class GLP-1 Drugs CSA Schedule Not a controlled drug Labeler / Supplier Eli Lilly and Company National Drug Code (NDC) 00002-1340 More about Zepbound (tirzepatide) Check interactions Compare alternatives Pricing & coupons Reviews (713) Drug images Latest FDA alerts (3) Side effects Dosage information During pregnancy Support group FDA approval history Drug class: GLP-1 Drugs Breastfeeding En espaol Patient resources Other brands Professional resources Other brands Related treatment guides Further information Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Indeed, our correlation analysis which suggests that greater weight loss is associated with greater pelvis BMD loss do align with prior work ( Another important consideration when evaluating the impact of these medications on bone health outcomes is the sustainability of GLP1Ra use as weight regain following cessation of treatment is expected ( To our knowledge, this is the first randomized trial to report clinically relevant bone outcomes following GLP1Ra use in older adults
In practical terms, participants on semaglutide still had 37% of a solid meal remaining in their stomach at the 4-hour mark
This dual mechanism distinguishes it from single-pathway GLP-1 agonists
Testosterone levels naturally decline as men age, leading to symptoms like fatigue, weight gain, low libido, and reduced mental clarity